Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Harmony Biosciences to post earnings of $0.74 per share and revenue of $201.25 million for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Harmony Biosciences Trading Down 0.9 %

Shares of Harmony Biosciences stock traded down $0.33 during trading on Friday, reaching $34.56. 667,803 shares of the company were exchanged, compared to its average volume of 542,346. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a twelve month low of $28.14 and a twelve month high of $41.61. The business has a 50-day moving average price of $36.57 and a 200-day moving average price of $35.79. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 0.47 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HRMY. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Cantor Fitzgerald lifted their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 30th. Mizuho decreased their price objective on Harmony Biosciences from $52.00 to $42.00 and set an "outperform" rating for the company in a research note on Thursday. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Wednesday. Finally, Needham & Company LLC decreased their target price on Harmony Biosciences from $52.00 to $50.00 and set a "buy" rating for the company in a research note on Wednesday. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $53.67.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 1,123 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sandip Kapadia sold 1,775 shares of the company's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.05, for a total value of $67,538.75. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock valued at $2,831,679 over the last three months. Company insiders own 30.80% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.